Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

Retrovirology

Mark A Wainberg¹  Wei Huang⁴  Christos J Petropoulos⁴  Yolanda Lie⁴  Diane N Singhroy¹  Yingshan Han²  Nathan Osman²  Peter K Quashie³  Thibault Mesplède² 

[1] Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montreal, Quebec, Canada;McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada;Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada;Monogram Biosciences, South San Francisco, California, USA

关键词: Strand-transfer assay;    Viral fitness;    Resistance to antiretrovirals;    Dolutegravir;    HIV integrase;   

Others  :  1209159
DOI  :  10.1186/1742-4690-10-22

 received in 2012-11-14, accepted in 2013-02-20,  发布年份 2013

【 摘 要 】

Background

Clinical studies have shown that integrase strand transfer inhibitors can be used to treat HIV-1 infection. Although the first-generation integrase inhibitors are susceptible to the emergence of resistance mutations that impair their efficacy in therapy, such resistance has not been identified to date in drug-naïve patients who have been treated with the second-generation inhibitor dolutegravir. During previous in vitro selection study, we identified a R263K mutation as the most common substitution to arise in the presence of dolutegravir with H51Y arising as a secondary mutation. Additional experiments reported here provide a plausible explanation for the absence of reported dolutegravir resistance among integrase inhibitor-naïve patients to date.

Results

We now show that H51Y in combination with R263K increases resistance to dolutegravir but is accompanied by dramatic decreases in both enzymatic activity and viral replication.

Conclusions

Since H51Y and R263K may define a unique resistance pathway to dolutegravir, our results are consistent with the absence of resistance mutations in antiretroviral drug-naive patients treated with this drug.

【 授权许可】

   
2013 Mesplède et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Wainberg MA, Zaharatos GJ, Brenner BG: Development of antiretroviral drug resistance. N Engl J Med 2011, 365:637-646.
• [2]Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S: Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012, 380(9849):1250-1258.
• [3]Wainberg MA: HIV-1 subtype distribution and the problem of drug resistance. AIDS 2004, 18(Suppl 3):S63-68.
• [4]Raffi F, Wainberg MA: Multiple choices for HIV therapy with integrase strand transfer inhibitors. Retrovirology 2012, 9:110. BioMed Central Full Text
• [5]Bar-Magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, Xu H, Wainberg MA: Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology 2009, 6:103. BioMed Central Full Text
• [6]Mesplede T, Quashie PK, Wainberg MA: Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS 2012, 7(5):401-408.
• [7]Pandey KK, Grandgenett DP: HIV-1 Integrase Strand Transfer Inhibitors: Novel Insights into their Mechanism of Action. Retrovirology 2008, 2:11-16.
• [8]Quashie PK, Mesplede T, Wainberg MA: HIV Drug Resistance and the Advent of Integrase Inhibitors. Current infectious disease reports 2012, 15(1):85-100.
• [9]Wainberg MA, Mesplede T, Quashie PK: The development of novel HIV integrase inhibitors and the problem of drug resistance. Current opinion in virology 2012, 2:656-662.
• [10]Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R: Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci 2011, 1222:83-89.
• [11]Wills T, Vega V: Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs 2012, 21:395-401.
• [12]Katlama C, Murphy R: Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs 2012, 21:523-530.
• [13]Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW: HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011, 203:1204-1214.
• [14]Bercoff DP, Triqueneaux P, Lambert C, Oumar AA, Ternes AM, Dao S, Goubau P, Schmit JC, Ruelle J: Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology 2010, 7:98. BioMed Central Full Text
• [15]Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrosky V, Almond S: Once-daily dolutegravir (DTG; S/GSK1349572) is non-inferior to raltegravir (RAL) in antiretroviral-naive adults: 48 week results from SPRING-2 (ING113086). Washington, DC, USA: XIX International AIDS Conference; 2012.
• [16]van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S: Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012, 12:111-118.
• [17]Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA: Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir. J Virol 2012, 86:2696-2705.
• [18]Jones G, Ledford R, Yu F, Chen X, Miller MD, Tsiang M, McColl D: In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Los Angeles, California: 14th CROI, Conference on Retroviruses and opportunistic infections; 2007.
• [19]Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M: Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008, 82:764-774.
• [20]Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, White KL, Miller MD: In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 2012, 93:288-296.
• [21]McColl D, Fransen S, Gupta SS, Parkin N, Margot N, Ledford R, Chen J, Chuck SL, Cheng AK, Miller MD: Resistance and cross-resistance to first generation integrase inhibitors; insights from a Phase 2 study of Elvitegravir (GS-9137). Barbados, West Indies: 16th International HIV Drug Resistance workshop; 2007.
• [22]Lutzke RA, Vink C, Plasterk RH: Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res 1994, 22:4125-4131.
• [23]Xue W, Liu H, Yao X: Molecular mechanism of HIV-1 integrase-vDNA interactions and strand transfer inhibitor action: a molecular modeling perspective. J Comput Chem 2012, 33:527-536.
• [24]Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA: Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010, 84:9210-9216.
• [25]Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P: Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011, 80:565-572.
• [26]Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vezinet F: The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 2011, 66:2827-2830.
• [27]Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A: In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011, 55:813-821.
• [28]Quinones-Mateu ME, Moore-Dudley DM, Jegede O, Weber J, Arts JA: Viral drug resistance and fitness. Adv Pharmacol 2008, 56:257-296.
• [29]Mbisa JL, Martin SA, Cane PA: Patterns of resistance development with integrase inhibitors in HIV. Infection and drug resistance 2011, 4:65-76.
• [30]Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL 3rd, Broderick T, Sigethy S: Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011, 55:4552-4559.
• [31]Fransen S, Gupta S, Frantzell A, Petropoulos CJ, Huang W: Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol 2012, 86:7249-7255.
• [32]Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA: Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 2011, 85:11300-11308.
• [33]Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P: Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464:232-236.